CN1634061A - Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process - Google Patents
Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process Download PDFInfo
- Publication number
- CN1634061A CN1634061A CN 200410040852 CN200410040852A CN1634061A CN 1634061 A CN1634061 A CN 1634061A CN 200410040852 CN200410040852 CN 200410040852 CN 200410040852 A CN200410040852 A CN 200410040852A CN 1634061 A CN1634061 A CN 1634061A
- Authority
- CN
- China
- Prior art keywords
- preparation
- acetaminophen
- gel
- clathrate
- anhydrous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 6
- 230000008569 process Effects 0.000 title abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 46
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 104
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 229960005489 paracetamol Drugs 0.000 claims description 52
- 239000000499 gel Substances 0.000 claims description 43
- 238000003756 stirring Methods 0.000 claims description 37
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 35
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 35
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 29
- 239000000758 substrate Substances 0.000 claims description 28
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 26
- 229930185605 Bisphenol Natural products 0.000 claims description 18
- 239000000679 carrageenan Substances 0.000 claims description 18
- 235000010418 carrageenan Nutrition 0.000 claims description 18
- 229920001525 carrageenan Polymers 0.000 claims description 18
- 229940113118 carrageenan Drugs 0.000 claims description 18
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical group [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 18
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 16
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 16
- 229920002581 Glucomannan Polymers 0.000 claims description 16
- 229920002752 Konjac Polymers 0.000 claims description 16
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims description 16
- 229940046240 glucomannan Drugs 0.000 claims description 16
- 239000000252 konjac Substances 0.000 claims description 16
- 235000010485 konjac Nutrition 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- 238000013019 agitation Methods 0.000 claims description 12
- 238000009833 condensation Methods 0.000 claims description 12
- 230000005494 condensation Effects 0.000 claims description 12
- 230000000249 desinfective effect Effects 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000008961 swelling Effects 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 9
- 229920001817 Agar Polymers 0.000 claims description 8
- 235000010489 acacia gum Nutrition 0.000 claims description 8
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000008272 agar Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229940023476 agar Drugs 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 241001312219 Amorphophallus konjac Species 0.000 claims 4
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 7
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 5
- 210000002345 respiratory system Anatomy 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 13
- 244000247812 Amorphophallus rivieri Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000002510 pyrogen Substances 0.000 description 5
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 4
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940063202 dextromethorphan hydrobromide 20 mg Drugs 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process, which is prepared from acetaminopher, d-pesudoephedrine hydrochloride, waterless Dextromethorphan Hydrobromide, and right amount of base material. The invention also discloses the process for preparing the medicament. By preparing into the form of gel type, children are willing to take the preparation, it has good effects for controlling children's virus infection of upper respiratory tract and treating children's common cold.
Description
Technical field: the present invention is the pseudo-anaesthetic thing of a kind of bis-phenol preparation and preparation method thereof, and particularly pseudo-numb gel preparation of bis-phenol and other preparation method belong to technical field of medicaments.
Technical background: flu also claims acute upper respiratory tract infection, is commonly encountered diseases and the frequently-occurring disease that influences human health.Cold virus has nearly 200 kinds, and children's is because health defensive enginery immaturity also, and a little less than the resistance against diseases, so that all must catch 6-7 time every year, Kai Fa children coryza medicine kind increases gradually in recent years, and dosage form is different; As: disclosed number of patent application is " 02110056 " in the Chinese patent communique, patent application, number of patent application that name is called " Rationed fenmameimin drops " are called the patent application of " U.S.A pounces on pseudo-numb dry suspension and processing technology " for " 00136032 ", name; They all are to be used for active drug that infantile common cold is prevented and treated; But antihistamine composition chlorphenamine maleate has all been used in two parts of applications, the effect of this composition is secretions drying and the thickness that makes lower respiratory tract, reduces sneeze and secretion Rhinorrhea, has slight sedation simultaneously, the patient is easily drowsiness, is unfavorable for the work and study on daytime.And the product that has gone on the market: the pseudo-sesame candy slurry of bis-phenol, adopted acetaminophen, selectivity to shrink the pseudoephedrine hydrochloride of upper respiratory tract blood capillary, the dextromethorphan hydrobromide of maincenter antitussive effect with antipyretic-antalgic, though product has good antipyretic-antalgic, antitussive, alleviates the congested curative effect of nasal mucosa, but be the dosage form kind at the children characteristics, infant uses existing product that certain difficulty, displeased acceptance are arranged.In the real life, child patient quantity is huge, and is poor to the ability to accept of general formulation, and the outward appearance of medicine, mouthfeel directly influence the application and the curative effect of medicine; Infantile common cold is a kind of commonly encountered diseases that has a strong impact on child health, the dosage form of selecting suitable prescription control children's upper respiratory tract viral infection and being suitable for child administration is setting about a little of research and development children coryza medicine, in view of the develop rapidly of medical science and these situations that deepen continuously that cold virus is studied, need exploitation effective medicine preparation that a kind of market prospect is wide, the child takes like a shot, the treatment of infantile common cold is reached a new high, thereby infantile common cold patient's quality of life is further improved.
Summary of the invention: the objective of the invention is to: the pseudo-anaesthetic thing of a kind of bis-phenol preparation and preparation method thereof is provided; The present invention is made into fruit jelly or the soft sweet type gel that liked by the child, and children's extremely is ready to take, and has reduced the adult and has advised the trouble of feeding, and is not only tasty, and therapeutical effect is good, has enriched the dosage form kind, and market prospect is very wide; And, select feasible substrate and technology rationally, product appearance, good mouthfeel at the pharmaceutical properties of ambroxol hydrochloride.
The present invention constitutes like this: the pseudo-anaesthetic thing of bis-phenol preparation: calculate according to weight, it is to be made into gel, injection by acetaminophen 1000～2000mg, pseudoephedrine hydrochloride 100～200mg, anhydrous dextromethorphan hydrobromide 20～80mg and appropriate amount of auxiliary materials, comprising: injection, powder pin, freeze-dried powder, dispersible tablet, soft capsule, drop pill, slow releasing preparation.Specifically: the pseudo-anaesthetic thing of this bis-phenol preparation: calculate according to weight, it is prepared into gel fruit jelly or soft sweet type gel oral formulations by acetaminophen 1000～2000mg, pseudoephedrine hydrochloride 100～200mg and anhydrous dextromethorphan hydrobromide 20～80mg and an amount of substrate, and wherein: substrate is one or more compositions of carrageenan, agar, carbomer, gelatin, sodium carboxymethyl cellulose or arabic gum.Specifically: the gel preparation that the substrate that the gel preparation of this product is mixed to obtain by 1: 2 part by weight by acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg and anhydrous dextromethorphan hydrobromide 50mg and Konjac glucomannan, carrageenan is prepared into is semifluid or solid gel shape.The gel preparation of indication of the present invention can also be by acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg and anhydrous dextromethorphan hydrobromide 50mg and carrageenan: agar: Konjac glucomannan: gelatin: sodium carboxymethyl cellulose: arabic gum=1: 1: 0.5: 1: 3: 1 part by weight mixes the substrate that obtains and is prepared from, the gel preparation that obtains, its shape that is translucent.The preparation method of the pseudo-anaesthetic thing of bis-phenol preparation: will be to acetyl-amino phenol, pseudoephedrine hydrochloride and anhydrous hydrobromic acid right U.S. husky and substrate mix homogeneously, after the sterilization promptly.Specifically: the gel in the described preparation prepares like this: by beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Konjac glucomannan, carrageenan are pressed 1: 2 part by weight mix homogeneously; under stirring condition; 0.8% mixed-matrix is put into cold water; make it to disperse; soak 20～30min, make the abundant water absorption and swelling of substrate, stir then, heat; filter; filter the back and add under condition of stirring acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide, mix homogeneously joins rapidly in the disinfecting container; seal; sterilization is cooled to about 30 ℃ condensation rapidly; drying, promptly.
Gel in the preparation of the present invention can also prepare like this: by beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; With carrageenan: agar: Konjac glucomannan: gelatin: sodium carboxymethyl cellulose: arabic gum=1: 1: 0.5: 1: 3: 1 part by weight mix homogeneously; under stirring condition; 0.8% mixed-matrix is put into cold water;, make it to disperse, soak 20～30min; make the abundant water absorption and swelling of substrate; stir then; heating is filtered, and filters the back and adds under condition of stirring acetyl-amino phenol clathrate; pseudoephedrine hydrochloride; anhydrous dextromethorphan hydrobromide; mix homogeneously; join rapidly in the disinfecting container, seal, sterilization; be cooled to rapidly about 30 ℃; condensation, drying, promptly.In preparation process, allow to add materials such as suitable flavoring agent or food coloring, with the color and luster that improves product, local flavor etc.
Compared with prior art, the application will have preparation now and change system into fruit jelly or the soft sweet type gel that liked by the child, children's extremely is ready to take, reduce the adult and advised the trouble of feeding, not only tasty, product has enriched the dosage form kind for control children's upper respiratory tract viral infection, treatment children's's flu function well, and market prospect is very wide.
The applicant finds in development process, the acetaminophen poor solubility, if directly make gel, the dissolubility of medicine, dissolution, bioavailability are all poor than liquid preparation; The more important thing is in the gel environment of humidity to be hydrolyzed into p-aminophenol that oxidation further takes place then, and color is pulverize redness, brown gradually, becomes black at last; And the kind of gel-type vehicle and consumption have played crucial effects to outward appearance, stability, the curative effect of product; As a kind of novel form, the release of medicine, to absorb whether desirable, gelling or the like be key problem in technology problem of the present invention.
The applicant has carried out a series of experiments, select to adopt beta-schardinger dextrin-at last: 3: 1 part by weight of acetaminophen, 6 hours mixing time, 30 ℃ temperature, technical conditions such as parcel acetaminophen etc., improved greatly medicine dissolution, improved the stability of product; The composite substrate of weight ratio that adopts Konjac glucomannan, carrageenan to press 1: 2, the product stability that makes, gel strength ideal, outward appearance is good, selects the supplementary product kind of preparation technology, use of pharmaceutical preparation provided by the invention and consumption, ratio etc., can guarantee its science, reasonable, feasible; The preparation that obtains has effective therapeutic effect.
Experimental example 1: acetaminophen clathrate technical study
(1) technical study
Group medicine: beta-schardinger dextrin-mixing time enclose temperature ℃ clathrate weight g clathrate content %
1 1∶8 6 50 6.44 11.2
2 1∶8 6 40 6.19 9.3
3 1∶8 6 30 5.38 8.7
4 1∶6 3 40 7.37 21.3
5 1∶6 3 30 7.42 16.8
6 1∶6 3 50 8.02 14.6
7 1∶3 1 30 10.29 38.5
8 1∶3 1 50 10.35 30.2
9 1∶3 1 40 10.08 22.3
The result shows that the clathrate optimum process condition of preparation is: beta-schardinger dextrin-: 3: 1 part by weight of acetaminophen, 6 hours mixing time, 30 ℃ temperature.
(2) release experiment
With 30 livers, the normal male rat of renal function (age about 3 months, 200～250g), be divided into 3 groups at random: the pseudo-numb syrup group of bis-phenol, do not prepare clathrate gel group, gel group of the present invention, 10 every group.Behind every group of rat fasting 12h, difference single-dose ambroxol hydrochloride sheet, ambroxol hydrochloride capsule and gel group of the present invention (dosage is 0.6mg), 2h advances unified feedstuff after the administration, in the back 0.5,1,2 of taking medicine, 5,10h extracts ulnar vein blood 2-3ml, and centrifugal 10min gets serum and places-20 ℃ of cryopreservation to measuring.Measurement result sees Table 3.
(* 10 for table 3 blood drug level-time data
-9G/ml)
Group 0.5h 1h 2h 5h 10h
The pseudo-numb syrup group 3.5 of bis-phenol ± 1.8 4.8 ± 1.1 3.8 ± 0.7 1.3 ± 0.5 0.3 ± 0.2
Do not prepare clathrate gel group 3.6 ± 1.1 4.0 ± 1.4 4.1 ± 1.0 3.6 ± 0.9 2.5 ± 0.5
Gel group 4.2 of the present invention ± 1.3 5.2 ± 3.4 4.1 ± 0.6 1.3 ± 0.4 0.5 ± 0.9
The result shows: after cyclodextrin and medicine form clathrate, the physicochemical property of acetaminophen changes to some extent, suppress hydrolysis, oxidation, improve dissolubility, the blood drug level of product of the present invention last stage after advancing medicine all is not less than liquid preparation, show gel of the present invention is entered the internal energy rapid absorption of body, reach valid density.
Experimental example 2: Study on Forming
(1) selection of matrix species
The ambroxol hydrochloride gel clarity of gel relatively
Substrates quantity % gel strength (g/cm
2)
Carrageenan 0.8 1665.2
Konjac glucomannan 0.8 1557.4
Carrageenan+Konjac glucomannan 0.8 1101.3
(2) screening of substrate composition and consumption
Konjac glucomannan: carrageenan consumption % mouthfeel
1: 1 0.6 crisp, difference of hardness, poor toughness, no bite
1: 1 0.8 crisp, difference of hardness, poor toughness, no bite
1: 1 1.0 crisp, difference of hardness, poor toughness, no bite
Hardness was moderate in 1: 2 0.6, and tough elasticity is relatively poor, and bite is arranged
Hardness was moderate in 1: 2 0.8, and tough good springiness has bite
Hardness was big in 1: 2 1.0, and tough elasticity is strong
Hardness was big in 1: 3 0.6, and tough elasticity is strong
Hardness was big in 1: 3 0.8, and tough elasticity is strong
Hardness was big in 1: 3 1.0, and tough elasticity is strong
The result shows: the best composite condition of substrate is a Konjac glucomannan: the part by weight of carrageenan=1: 2, consumption is 0.8%.
(3) study on the stability
0 month 6 months March December
The group color indicates content % color and indicates content % color sign content % color sign content %
Do not wrap up gel yellowish 99.8 yellowish 99.7 brown 98.0 dark brown 97.5
Gel of the present invention yellowish 99.9 yellowish 99.8 yellowish 99.6 yellowish 99.6
The result shows: after cyclodextrin and medicine formed clathrate, the physicochemical property of acetaminophen changed to some extent, suppressed hydrolysis, oxidation, had improved preparation stability.
Experimental example 3: pharmacodynamic experiment
The experimentation of antipyretic effect
The experiment material animal: healthy New Zealand large ear rabbit, body weight (2.4 ± 0.3) kg, male and female have concurrently; Medicine: medicine A: according to method preparation of the present invention, medicine B: the pseudo-sesame candy slurry of bis-phenol; Instrument: computer numeral clinical thermometer.
Experimental technique: get 24 of health large ear rabbits, 3d before the experiment, at room temperature 22-25 ℃, humidity is that every interval was surveyed animal anus temperature in 1 hour 1 time totally 4 times under the 55%-65% ventilated environment, animal is adapted to, and the animal of selection body temperature fluctuation range in 0.4 ℃ of scope is standby.During experiment animal is divided into 4 groups at random by the body weight size, is respectively normal saline group, A group, B group.Survey rabbit anus temperature 1 time every 30min with the computer digital clinical thermometer, survey altogether 3 times, ask for its meansigma methods and be this animal basal body temperature.Press 1ml/kg administration rabbit ear edge intravenous injection deactivation escherichia coli pyrogenicity, and before pyrogenicity 30 minutes gastric infusions at twice after 30min and the pyrogenicity.After pyrogenicity 30,60,120,240 and 360min survey rabbit anus temperature respectively 5 times, calculate the difference respectively organize rabbit day part treatment back anus temperature and basal body temperature, processing takes statistics.
Each different period body temperature situation of change in treated animal treatment back
The group treatment back time (min)
30 60 120 240 360
Normal saline group 0.47 ± 0.39 1.33 ± 0.24 2.20 ± 0.05 1.58 ± 0.15 0.84 ± 0.14
Treatment A group 0.34 ± 0.17 0.82 ± 0.47 0.92 ± 0.47 0.51 ± 0.18 0.33 ± 0.15
Treatment B group 0.37 ± 0.29 0.84 ± 0.29 0.99 ± 0.24 0.55 ± 0.23 0.44 ± 0.27
The result shows: the A group has obvious antipyretic effect to escherichia coli pyrogenicity rabbit, and its effect of bringing down a fever is not less than and is better than the B group, and antipyretic effect is lasting than the B group.
Concrete embodiment:
Embodiments of the invention 1:
Acetaminophen 2000mg, pseudoephedrine hydrochloride 200mg, anhydrous dextromethorphan hydrobromide 80mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; With Konjac glucomannan; carrageenan is pressed 1: 2 part by weight mix homogeneously; under stirring condition; 0.8% mixed-matrix is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then; heating; filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate; pseudoephedrine hydrochloride; anhydrous dextromethorphan hydrobromide, mix homogeneously; join rapidly in the disinfecting container; seal, sterilization is cooled to rapidly about 30 ℃; condensation; drying promptly gets gel, this product oral; three times on the one; each 2 bags; every bag 10 gram.
Embodiments of the invention 2:
Acetaminophen 1000mg, pseudoephedrine hydrochloride 100mg, anhydrous dextromethorphan hydrobromide 20mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; With carrageenan: agar: Konjac glucomannan: gelatin: sodium carboxymethyl cellulose: arabic gum=1: 1: 0.5: 1: 3: 1 part by weight mix homogeneously; under stirring condition; 0.8% mixed-matrix is put into cold water; make it to disperse; soak 20～30min, make the abundant water absorption and swelling of substrate, stir then; heating; filter; filtering the back adds under condition of stirring acetyl-amino phenol clathrate; pseudoephedrine hydrochloride; anhydrous dextromethorphan hydrobromide, mix homogeneously joins rapidly in the disinfecting container; seal; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Embodiments of the invention 3:
Acetaminophen 2000mg, pseudoephedrine hydrochloride 200mg, anhydrous dextromethorphan hydrobromide 80mg
Get acetaminophen, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide, press medicine: substrate=1: 1.4, the mixed-matrix of adding soybean oil, soybean lecithin, heating and melting, mixing gets soft capsule content; The preparation of glue: with gelatin: glycerol: water=1: 0.3: 0.7, get gelatin and add an amount of distilled water and make its imbibition, glycerol and remaining water are put be heated to 70～80 ℃ in the glue pot in addition, mix homogeneously adds expansible gelatin and stirs, and makes it to dissolve into uniform glue, in 70 ℃ of insulations 1～2 hour, leave standstill, remove the come-up foam, filter with cloth bag, in encapsulating machine, be pressed into soft capsule, be pressed into soft capsule, put in the drum drying machine and finalize the design, whole ball, drying promptly gets soft capsule.
Embodiments of the invention 4:
Acetaminophen 1000mg, pseudoephedrine hydrochloride 100mg, anhydrous dextromethorphan hydrobromide 20mg
Get acetaminophen, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide, splash into the ratio that adopts PEG6000 and PEG4000 and be in 4: 3 the mixed-matrix, the water dropper model adopts No. 2 water droppers, and coolant temperature is 18～20 ℃, promptly gets drop pill.
Embodiments of the invention 5:
Acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg, anhydrous dextromethorphan hydrobromide 50mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Carrageenan with 0.8% under stirring condition, is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then, heat, filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide; mix homogeneously joins rapidly in the disinfecting container, seals; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Embodiments of the invention 6:
Acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg, anhydrous dextromethorphan hydrobromide 50mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Agar with 0.7% under stirring condition, is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then, heat, filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide; mix homogeneously joins rapidly in the disinfecting container, seals; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Embodiments of the invention 7:
Acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg, anhydrous dextromethorphan hydrobromide 50mg are by beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Gelatin with 0.8% under stirring condition, is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then, heat, filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide; mix homogeneously joins rapidly in the disinfecting container, seals; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Embodiments of the invention 8:
Acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg, anhydrous dextromethorphan hydrobromide 50mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Konjac glucomannan with 1.2% under stirring condition, is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then, heat, filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide; mix homogeneously joins rapidly in the disinfecting container, seals; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Embodiments of the invention 9:
Acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg, anhydrous dextromethorphan hydrobromide 50mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Sodium carboxymethyl cellulose with 1.3% under the stirring condition, is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then, heat, filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide; mix homogeneously joins rapidly in the disinfecting container, seals; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Embodiments of the invention 10:
Acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg, anhydrous dextromethorphan hydrobromide 50mg
By beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Arabic gum with 1.1% under stirring condition, is put into cold water; make it to disperse, soak 20～30min, make the abundant water absorption and swelling of substrate; stir then, heat, filter, filter the back and under condition of stirring, add acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide; mix homogeneously joins rapidly in the disinfecting container, seals; sterilization is cooled to about 30 ℃ condensation rapidly; drying promptly gets gel.
Claims (7)
1, the pseudo-anaesthetic thing of a kind of bis-phenol preparation, it is characterized in that: calculate according to weight, it is to be made into gel, injection by acetaminophen 1000～2000mg, pseudoephedrine hydrochloride 100～200mg and anhydrous dextromethorphan hydrobromide 20～80mg and appropriate amount of auxiliary materials, comprising: injection, powder pin, freeze-dried powder, dispersible tablet, soft capsule, drop pill, slow releasing preparation.
2, according to the pseudo-anaesthetic thing of the described bis-phenol of claim 1 preparation, it is characterized in that: calculate according to weight, it is prepared into gel fruit jelly or soft sweet type gel oral formulations by acetaminophen 1000～2000mg, pseudoephedrine hydrochloride 100～200mg and anhydrous dextromethorphan hydrobromide 20～80mg and an amount of substrate, and wherein: substrate is one or more compositions of carrageenan, agar, carbomer, gelatin, sodium carboxymethyl cellulose or arabic gum.
3, according to claim 1 or the pseudo-anaesthetic thing of 2 described bis-phenols preparation, it is characterized in that: the gel preparation that the substrate that it is mixed to obtain by 1: 2 part by weight by acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg and anhydrous dextromethorphan hydrobromide 50mg and Konjac glucomannan, carrageenan is prepared into is semifluid or solid gel shape.
4, according to claim 1 or the pseudo-anaesthetic thing of 2 described bis-phenols preparation, it is characterized in that: it is by acetaminophen 1600mg, pseudoephedrine hydrochloride 150mg and anhydrous dextromethorphan hydrobromide 50mg and carrageenan: agar: Konjac glucomannan: gelatin: sodium carboxymethyl cellulose: arabic gum=1: 1: 0.5: 1: 3: 1 part by weight mixes the substrate that obtains and is prepared from, the gel preparation that obtains, its shape that is translucent.
5, as the preparation method of the pseudo-anaesthetic thing of bis-phenol as described in the claim 1～4 any preparation, it is characterized in that: will be to acetyl-amino phenol, pseudoephedrine hydrochloride and anhydrous hydrobromic acid right U.S. husky and substrate mix homogeneously, after the sterilization promptly.
6, preparation method according to the pseudo-anaesthetic thing of the described bis-phenol of claim 5 preparation, it is characterized in that: the gel in the described preparation prepares like this: by beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; Konjac glucomannan, carrageenan are pressed 1: 2 part by weight mix homogeneously; under stirring condition; 0.8% mixed-matrix is put into cold water; make it to disperse; soak 20～30min, make the abundant water absorption and swelling of substrate, stir then, heat; filter; filter the back and add under condition of stirring acetyl-amino phenol clathrate, pseudoephedrine hydrochloride, anhydrous dextromethorphan hydrobromide, mix homogeneously joins rapidly in the disinfecting container; seal; sterilization is cooled to about 30 ℃ condensation rapidly; drying, promptly.
7, preparation method according to the pseudo-anaesthetic thing of the described bis-phenol of claim 5 preparation, it is characterized in that: the gel in the described preparation prepares like this: by beta-schardinger dextrin-: acetaminophen is that 3: 1 part by weight takes by weighing beta-schardinger dextrin-, beta-schardinger dextrin-is dissolved in 30 ℃ of thermostatted water solution, add corresponding acetaminophen separately, after the 250rmin magnetic agitation 4 hours, drop to room temperature gradually, the clathrate suspension that forms was left standstill in refrigerator 24 hours, sucking filtration, discard filtrate, drain back 50 ℃ of cold drying with distilled water wash, must be to acetyl-amino phenol clathrate; With carrageenan: agar: Konjac glucomannan: gelatin: sodium carboxymethyl cellulose: arabic gum=1: 1: 0.5: 1: 3: 1 part by weight mix homogeneously; under stirring condition; 0.8% mixed-matrix is put into cold water;, make it to disperse, soak 20～30min; make the abundant water absorption and swelling of substrate; stir then; heating is filtered, and filters the back and adds under condition of stirring acetyl-amino phenol clathrate; pseudoephedrine hydrochloride; anhydrous dextromethorphan hydrobromide; mix homogeneously; join rapidly in the disinfecting container, seal, sterilization; be cooled to rapidly about 30 ℃; condensation, drying, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040852 CN1634061A (en) | 2004-10-11 | 2004-10-11 | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040852 CN1634061A (en) | 2004-10-11 | 2004-10-11 | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634061A true CN1634061A (en) | 2005-07-06 |
Family
ID=34845876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410040852 Pending CN1634061A (en) | 2004-10-11 | 2004-10-11 | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634061A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100448431C (en) * | 2005-10-17 | 2009-01-07 | 重庆医药工业研究院有限责任公司 | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn |
| CN101596158B (en) * | 2008-06-04 | 2011-03-30 | 北京科信必成医药科技发展有限公司 | Compound slow release preparation of acetyl aminophenol, pseudoephedrine and dextromethorphan |
| CN102225065A (en) * | 2011-04-28 | 2011-10-26 | 海南新中正制药有限公司 | Parcetamol pseudoephedrine hydrochloride and dextromethorphan hydrochloride capsule and preparation method thereof |
| CN103110629A (en) * | 2013-02-19 | 2013-05-22 | 青岛正大海尔制药有限公司 | Compound phenol caplets dropping pills and preparation method thereof |
| CN103536527A (en) * | 2013-09-16 | 2014-01-29 | 南通丝乡丝绸有限公司 | Dextromethorphan hydrobromide injection and preparation method thereof |
| CN103536539A (en) * | 2013-09-16 | 2014-01-29 | 南通丝乡丝绸有限公司 | Dextromethorphan hydrobromide lyophilized powder and preparation method thereof |
| CN110025568A (en) * | 2019-03-06 | 2019-07-19 | 广州中天康顺生物医药有限公司 | A kind of thixotroping pharmaceutical hydrogel matrix and its shaddock ped glycosides formulation and preparation method |
-
2004
- 2004-10-11 CN CN 200410040852 patent/CN1634061A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100448431C (en) * | 2005-10-17 | 2009-01-07 | 重庆医药工业研究院有限责任公司 | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn |
| CN101596158B (en) * | 2008-06-04 | 2011-03-30 | 北京科信必成医药科技发展有限公司 | Compound slow release preparation of acetyl aminophenol, pseudoephedrine and dextromethorphan |
| CN102225065A (en) * | 2011-04-28 | 2011-10-26 | 海南新中正制药有限公司 | Parcetamol pseudoephedrine hydrochloride and dextromethorphan hydrochloride capsule and preparation method thereof |
| CN102225065B (en) * | 2011-04-28 | 2013-05-15 | 海南新中正制药有限公司 | Parcetamol pseudoephedrine hydrochloride and dextromethorphan hydrochloride capsule and preparation method thereof |
| CN103110629A (en) * | 2013-02-19 | 2013-05-22 | 青岛正大海尔制药有限公司 | Compound phenol caplets dropping pills and preparation method thereof |
| CN103536527A (en) * | 2013-09-16 | 2014-01-29 | 南通丝乡丝绸有限公司 | Dextromethorphan hydrobromide injection and preparation method thereof |
| CN103536539A (en) * | 2013-09-16 | 2014-01-29 | 南通丝乡丝绸有限公司 | Dextromethorphan hydrobromide lyophilized powder and preparation method thereof |
| CN103536539B (en) * | 2013-09-16 | 2015-03-25 | 南通丝乡丝绸有限公司 | Dextromethorphan hydrobromide lyophilized powder and preparation method thereof |
| CN110025568A (en) * | 2019-03-06 | 2019-07-19 | 广州中天康顺生物医药有限公司 | A kind of thixotroping pharmaceutical hydrogel matrix and its shaddock ped glycosides formulation and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1281356A (en) | Quickly soluble solid preparations | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1634061A (en) | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process | |
| CN1634060A (en) | Gelatin formulation of dextromethorphan hydrobromide and its preparing method | |
| CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
| CN1679763A (en) | Gel preparation of mulberry leaf and chrysanthemum and its preparing method | |
| CN1626143A (en) | Medication for treating pharyngitis | |
| CN1634059A (en) | Pseudoephedrine hydrochloride, dextromethorphan hydrobromide and chlorphenamine maleates gel formulation and its preparing process | |
| CN1197556C (en) | Tablet disintegzated in mouth rapidly for preventing and curing vomit and preparing method | |
| CN1739645A (en) | A traditional Chinese medicine preparation of Kechuanling for children and its preparation method | |
| CN1660275A (en) | 'Ganmaoning' gel preparation for enfant and preparation method | |
| CN1660265A (en) | Gel preparation of dual goldthread root and preparing method | |
| CN1634073A (en) | Orally disintegrating tablet of levofloxacin and its pharmaceutical salt | |
| CN1626145A (en) | Medication for treating cough | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1915324A (en) | Pediatric Fupi preparation and preparation method thereof | |
| CN101081227B (en) | Composition of diammonium glycyrrhizinate | |
| CN1775271A (en) | Hyperfunction-inhibiting preparation and new preparing method | |
| CN1626124A (en) | Drop pills of medical broth of small bupleurum root | |
| CN1686484A (en) | Bastard feverfew throat clearing drip pill and its preparation method | |
| CN1634478A (en) | Tendril-leaved fritillary bulb loquat drop pills and preparation method thereof | |
| CN1634145A (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN1283231C (en) | Orally disintegrating tablet and its preparation | |
| CN1634011A (en) | Ibuprofen gelling preparation and its preparation method | |
| CN1634373A (en) | Compound licorice root medicinal preparation and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |